Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G

R. Sakuma; J. A. Noser; S. Ohmine; Y. Ikeda

doi:10.1038/sj.gt.3302852

Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G

R. Sakuma, J. A. Noser, S. Ohmine, Y. Ikeda

Molecular Medicine

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Old World monkey TRIM5α targets incoming human immunodeficiency virus type 1 (HIV-1) viral capsid, whereas the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3 family hypermutate/degrade viral sequences. Here, we show the potentials of simian TRIM5α and APOBEC3G as therapeutic sequences for AIDS gene therapy. Both rhesus and African green monkey (agm) TRIM5α efficiently restrict HIV-1 vectors with divergent Gag from different HIV-1 subtypes. Human T cells genetically engineered to express agm-TRIM5α block or delay HIV-1 replication. Although agm-APOBEC3G expression alone only transiently suppresses HIV-1 replication, co-expression of agm-APOBEC3G and agm-TRIM5α successfully block the virus replication for more than 5 weeks.

Original language	English (US)
Pages (from-to)	185-189
Number of pages	5
Journal	Gene Therapy
Volume	14
Issue number	2
DOIs	https://doi.org/10.1038/sj.gt.3302852
State	Published - Jan 2007

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Genetics

Access to Document

10.1038/sj.gt.3302852

Cite this

@article{beb1eb99c37d4e1eb2155be27226575f,

title = "Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G",

abstract = "Old World monkey TRIM5α targets incoming human immunodeficiency virus type 1 (HIV-1) viral capsid, whereas the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3 family hypermutate/degrade viral sequences. Here, we show the potentials of simian TRIM5α and APOBEC3G as therapeutic sequences for AIDS gene therapy. Both rhesus and African green monkey (agm) TRIM5α efficiently restrict HIV-1 vectors with divergent Gag from different HIV-1 subtypes. Human T cells genetically engineered to express agm-TRIM5α block or delay HIV-1 replication. Although agm-APOBEC3G expression alone only transiently suppresses HIV-1 replication, co-expression of agm-APOBEC3G and agm-TRIM5α successfully block the virus replication for more than 5 weeks.",

author = "R. Sakuma and Noser, {J. A.} and S. Ohmine and Y. Ikeda",

note = "Funding Information: We thank Dr Greg J Towers, University College London for reagents and helpful discussion. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 174xCEM from Dr Peter Cresswell, GHOST(3)R3/X4/R5 from Dr Vineet N KewalRamani and Dr Dan R Littman, p89.6 from Dr Ronald G Collman, pNL4-3 from Dr Malcolm Martin and pc-AGM-APO-BEC3G-HA from Dr Nathaniel Landau. This work was supported by the Mayo Foundation (to YI).",

year = "2007",

month = jan,

doi = "10.1038/sj.gt.3302852",

language = "English (US)",

volume = "14",

pages = "185--189",

journal = "Gene Therapy",

issn = "0969-7128",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G

AU - Sakuma, R.

AU - Noser, J. A.

AU - Ohmine, S.

AU - Ikeda, Y.

N1 - Funding Information: We thank Dr Greg J Towers, University College London for reagents and helpful discussion. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: 174xCEM from Dr Peter Cresswell, GHOST(3)R3/X4/R5 from Dr Vineet N KewalRamani and Dr Dan R Littman, p89.6 from Dr Ronald G Collman, pNL4-3 from Dr Malcolm Martin and pc-AGM-APO-BEC3G-HA from Dr Nathaniel Landau. This work was supported by the Mayo Foundation (to YI).

PY - 2007/1

Y1 - 2007/1

N2 - Old World monkey TRIM5α targets incoming human immunodeficiency virus type 1 (HIV-1) viral capsid, whereas the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3 family hypermutate/degrade viral sequences. Here, we show the potentials of simian TRIM5α and APOBEC3G as therapeutic sequences for AIDS gene therapy. Both rhesus and African green monkey (agm) TRIM5α efficiently restrict HIV-1 vectors with divergent Gag from different HIV-1 subtypes. Human T cells genetically engineered to express agm-TRIM5α block or delay HIV-1 replication. Although agm-APOBEC3G expression alone only transiently suppresses HIV-1 replication, co-expression of agm-APOBEC3G and agm-TRIM5α successfully block the virus replication for more than 5 weeks.

AB - Old World monkey TRIM5α targets incoming human immunodeficiency virus type 1 (HIV-1) viral capsid, whereas the apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3 family hypermutate/degrade viral sequences. Here, we show the potentials of simian TRIM5α and APOBEC3G as therapeutic sequences for AIDS gene therapy. Both rhesus and African green monkey (agm) TRIM5α efficiently restrict HIV-1 vectors with divergent Gag from different HIV-1 subtypes. Human T cells genetically engineered to express agm-TRIM5α block or delay HIV-1 replication. Although agm-APOBEC3G expression alone only transiently suppresses HIV-1 replication, co-expression of agm-APOBEC3G and agm-TRIM5α successfully block the virus replication for more than 5 weeks.

UR - http://www.scopus.com/inward/record.url?scp=33845989508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845989508&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302852

DO - 10.1038/sj.gt.3302852

M3 - Article

C2 - 16943852

AN - SCOPUS:33845989508

SN - 0969-7128

VL - 14

SP - 185

EP - 189

JO - Gene Therapy

JF - Gene Therapy

IS - 2

ER -

Inhibition of HIV-1 replication by simian restriction factors, TRIM5α and APOBEC3G

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this